Table 1 Baseline patient characteristics.

From: Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients

Variables

1 L N = 29

 > 2 L N = 19

Total N = 48

Median age, years (range)

76 (56–84)

70 (58–84)

74 (56–84)

PSA, ng/mL

 < 100

26 (90%)

7 (37%)

33 (69%)

 ≥ 100

3 (10%)

12 (63%)

15 (31%)

Bone metastases

 Absent

7 (24%)

3 (16%)

10 (21%)

 Present

22 (76%)

16 (84%)

38 (79%)

Visceral metastases

 Absent

26 (90%)

13 (68%)

39 (81%)

 Present

3 (10%)

6 (32%)

9 (19%)

Number of metastatic sites

   

 = 1 site

11 (38%)

6 (32%)

17 (35%)

  > 1 site

18 (62%)

13 (68%)

31 (65%)

  1. 1 L = patients starting first-line treatment for mCRPC; > 2 L = pretreated patient cohort.